PL3100725T3 - Środek wzmacniający efekt rehabilitacji po uszkodzeniu nerwu zawierający pochodną eteru alkilowego lub jej sól - Google Patents

Środek wzmacniający efekt rehabilitacji po uszkodzeniu nerwu zawierający pochodną eteru alkilowego lub jej sól

Info

Publication number
PL3100725T3
PL3100725T3 PL15743367T PL15743367T PL3100725T3 PL 3100725 T3 PL3100725 T3 PL 3100725T3 PL 15743367 T PL15743367 T PL 15743367T PL 15743367 T PL15743367 T PL 15743367T PL 3100725 T3 PL3100725 T3 PL 3100725T3
Authority
PL
Poland
Prior art keywords
salt
alkyl ether
enhancing agent
nerve injury
ether derivative
Prior art date
Application number
PL15743367T
Other languages
English (en)
Inventor
Takuya Takahashi
Tomohiro Okuda
Original Assignee
Fujifilm Toyama Chemical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Toyama Chemical Co., Ltd. filed Critical Fujifilm Toyama Chemical Co., Ltd.
Publication of PL3100725T3 publication Critical patent/PL3100725T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5052Proteins, e.g. albumin
    • A61K9/5057Gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL15743367T 2014-01-31 2015-01-30 Środek wzmacniający efekt rehabilitacji po uszkodzeniu nerwu zawierający pochodną eteru alkilowego lub jej sól PL3100725T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014017587 2014-01-31
PCT/JP2015/052617 WO2015115582A1 (ja) 2014-01-31 2015-01-30 アルキルエーテル誘導体またはその塩を含有する神経損傷後のリハビリテーション効果促進剤
EP15743367.3A EP3100725B1 (en) 2014-01-31 2015-01-30 Post nerve injury rehabilitation effect-enhancing agent comprising an alkyl ether derivative or a salt thereof

Publications (1)

Publication Number Publication Date
PL3100725T3 true PL3100725T3 (pl) 2020-11-16

Family

ID=53757150

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15743367T PL3100725T3 (pl) 2014-01-31 2015-01-30 Środek wzmacniający efekt rehabilitacji po uszkodzeniu nerwu zawierający pochodną eteru alkilowego lub jej sól

Country Status (26)

Country Link
US (2) US10039744B2 (pl)
EP (1) EP3100725B1 (pl)
JP (3) JP5837726B1 (pl)
KR (1) KR102346219B1 (pl)
CN (1) CN106061478B (pl)
AU (1) AU2015211753B2 (pl)
BR (1) BR112016017747A2 (pl)
CA (1) CA2938184C (pl)
CY (1) CY1123154T1 (pl)
DK (1) DK3100725T3 (pl)
ES (1) ES2792950T3 (pl)
HR (1) HRP20200796T1 (pl)
HU (1) HUE050400T2 (pl)
IL (1) IL246925B (pl)
LT (1) LT3100725T (pl)
MX (1) MX2016009751A (pl)
MY (1) MY179290A (pl)
PH (1) PH12016501507A1 (pl)
PL (1) PL3100725T3 (pl)
PT (1) PT3100725T (pl)
RS (1) RS60462B1 (pl)
RU (1) RU2680247C2 (pl)
SG (2) SG10201907035TA (pl)
SI (1) SI3100725T1 (pl)
SM (1) SMT202000395T1 (pl)
WO (1) WO2015115582A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5837726B1 (ja) * 2014-01-31 2015-12-24 富山化学工業株式会社 アルキルエーテル誘導体またはその塩を含有する神経損傷後のリハビリテーション効果促進剤
WO2017111005A1 (ja) * 2015-12-25 2017-06-29 富山化学工業株式会社 1-(3-(2-(1-ベンゾチオフェン-5-イル)エトキシ)プロピル)アゼチジン-3-オールまたはその塩を含む錠剤
CN110167551B (zh) * 2016-12-28 2022-06-14 富士胶片富山化学株式会社 医药组合物
US20190336476A1 (en) * 2016-12-28 2019-11-07 Fujifilm Toyama Chemical Co., Ltd. Pharmaceutical composition
CN110167552B (zh) * 2016-12-28 2023-05-02 富士胶片富山化学株式会社 医药组合物及其制造方法
US20190343796A1 (en) * 2016-12-28 2019-11-14 Fujifilm Toyama Chemical Co., Ltd. Composition for external use
MX393052B (es) 2017-06-02 2025-03-24 Fujifilm Toyama Chemical Co Ltd Agente para prevenir o tratar atrofia cerebral.
US11666551B2 (en) * 2017-06-02 2023-06-06 Fujifilm Toyama Chemical Co., Ltd. Agent for reducing amount of amyloid β protein
KR20220101001A (ko) * 2017-06-02 2022-07-18 후지필름 도야마 케미컬 가부시키가이샤 타우병증 예방 또는 치료제
WO2018221728A1 (ja) 2017-06-02 2018-12-06 富山化学工業株式会社 アルツハイマー型認知症予防または治療剤
MX393700B (es) * 2017-06-02 2025-03-24 Fujifilm Toyama Chemical Co Ltd Agente para prevenir o tratar la ataxia espinocerebelosa.
EP3705121B1 (en) 2017-10-30 2023-08-30 FUJIFILM Toyama Chemical Co., Ltd. Emopamil binding protein binding agent and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4398247B2 (ja) 2001-10-19 2010-01-13 富山化学工業株式会社 アルキルエーテル誘導体またはその塩
US7753054B2 (en) 2001-11-29 2010-07-13 Japan Science And Technology Agency Method of constructing spinal injury model monkey and utilization thereof
USRE42327E1 (en) * 2002-06-14 2011-05-03 Toyama Chemical Co., Ltd. Medicinal compositions improving brain function and method for improving brain function
PL1614419T3 (pl) * 2003-04-17 2013-01-31 Toyama Chemical Co Ltd Środek zapobiegawczy/lek przeciwko chorobom nerwu wzrokowego zawierający pochodne eteru alkilowego lub ich sole
RU2397169C2 (ru) * 2005-03-28 2010-08-20 Тояма Кемикал Ко., Лтд. Способ получения 1-(3-(2-(1-бензотиофен-5-ил)этокси) пропил)азетидин-3-ола или его солей
SI2248809T1 (sl) 2005-03-28 2012-09-28 Toyama Chemical Co Ltd Alkil-3-(2-(benzo(b)tiofen-5-il)-etoksi)-propanoati kot vmesniki v proizvodnji derivatov azetidin-3-ola
US20090093453A1 (en) * 2006-04-26 2009-04-09 Toyama Chemical Co., Ltd Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
US8119625B2 (en) * 2006-04-26 2012-02-21 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
JP5837726B1 (ja) * 2014-01-31 2015-12-24 富山化学工業株式会社 アルキルエーテル誘導体またはその塩を含有する神経損傷後のリハビリテーション効果促進剤

Also Published As

Publication number Publication date
MY179290A (en) 2020-11-03
KR102346219B1 (ko) 2022-01-04
RS60462B1 (sr) 2020-07-31
HUE050400T2 (hu) 2020-12-28
JPWO2015115582A1 (ja) 2017-03-23
JP5837726B1 (ja) 2015-12-24
CY1123154T1 (el) 2021-10-29
MX2016009751A (es) 2016-11-08
SG11201606173TA (en) 2016-08-30
EP3100725A4 (en) 2017-08-30
JP2020073542A (ja) 2020-05-14
LT3100725T (lt) 2020-08-10
IL246925B (en) 2019-10-31
EP3100725A1 (en) 2016-12-07
BR112016017747A2 (pt) 2017-08-08
RU2016135236A (ru) 2018-03-02
US10039744B2 (en) 2018-08-07
CN106061478B (zh) 2019-04-30
SG10201907035TA (en) 2019-09-27
SI3100725T1 (sl) 2020-08-31
US20170165227A1 (en) 2017-06-15
PH12016501507A1 (en) 2017-02-06
RU2016135236A3 (pl) 2018-08-30
HRP20200796T1 (hr) 2020-08-07
JP2016074676A (ja) 2016-05-12
US10471044B2 (en) 2019-11-12
KR20160113281A (ko) 2016-09-28
US20180289668A1 (en) 2018-10-11
JP6825074B2 (ja) 2021-02-03
CN106061478A (zh) 2016-10-26
WO2015115582A1 (ja) 2015-08-06
CA2938184A1 (en) 2015-08-06
SMT202000395T1 (it) 2020-09-10
ES2792950T3 (es) 2020-11-12
IL246925A0 (en) 2016-09-29
AU2015211753B2 (en) 2019-09-12
NZ722542A (en) 2021-07-30
CA2938184C (en) 2021-11-23
EP3100725B1 (en) 2020-05-06
RU2680247C2 (ru) 2019-02-19
AU2015211753A1 (en) 2016-08-11
DK3100725T3 (da) 2020-06-22
HK1226298A1 (en) 2017-09-29
PT3100725T (pt) 2020-06-17
JP6642914B2 (ja) 2020-02-12

Similar Documents

Publication Publication Date Title
PL3100725T3 (pl) Środek wzmacniający efekt rehabilitacji po uszkodzeniu nerwu zawierający pochodną eteru alkilowego lub jej sól
GB201809461D0 (en) Leg movement stimulator device
ZA201607866B (en) Solid-stabilized emulsion
DK3233221T3 (da) Træningsindretning
IL249356A0 (en) A derivative of 2-acylaminothiazole or a salt thereof
PL2918316T3 (pl) Przyrząd do trenowania boksu
PL3018257T3 (pl) Słupek bariery
SG11201607387PA (en) Implement for training facial muscle
EP3380137C0 (en) AUTOMATIC INJECTOR DEVICE
PL3085227T3 (pl) Trenażer ruchu dla małych zwierząt
GB201608979D0 (en) Intraosseous infusion training system
GB2526178B (en) Horse-riding training device
GB2532578B (en) Animal amusement device
GB201405348D0 (en) Training cassette for auto-injector
GB201401108D0 (en) A training device
GB2522069B (en) Bird guard device
GB2524086B (en) A deterrent device
GB201402820D0 (en) Fence attachment device
GB2546148B (en) Animal deterrent
ZA201705079B (en) Deterrent device
GB201615786D0 (en) Animal training aid
GB201516639D0 (en) Attachment for boxing training devices
GB201415801D0 (en) Cat Fight Deterrent Colar
UA31160S (uk) Комбінезон для фітнесу
ES1144811Y (es) Aparato de musculación